199 related articles for article (PubMed ID: 32745161)
21. Gene Expression Profiling Prognostication of Posterior Uveal Melanoma: Does Size Matter?
Binkley EM; Bena JF; Davanzo JM; Hinz C; Boldt HC; Singh AD
Ophthalmol Retina; 2020 Jun; 4(6):620-629. PubMed ID: 32081600
[TBL] [Abstract][Full Text] [Related]
22. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Amaral T; Sinnberg T; Chatziioannou E; Niessner H; Leiter U; Keim U; Forschner A; Dwarkasing J; Tjien-Fooh F; Wever R; Flatz L; Eggermont A; Forchhammer S
Eur J Cancer; 2023 Mar; 182():155-162. PubMed ID: 36739215
[TBL] [Abstract][Full Text] [Related]
23. CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA.
Berry DE; Schefler AC; Seider MI; Materin M; Stinnett S; Mruthyunjaya P;
Retina; 2020 Feb; 40(2):214-224. PubMed ID: 31972790
[TBL] [Abstract][Full Text] [Related]
24. Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma.
Marchetti MA; Dusza SW; Bartlett EK
JAMA Dermatol; 2022 Jun; 158(6):680-683. PubMed ID: 35475908
[TBL] [Abstract][Full Text] [Related]
25. Predictive accuracy of risk prediction models for recurrence, metastasis and survival for early-stage cutaneous melanoma: a systematic review.
Kunonga TP; Kenny RPW; Astin M; Bryant A; Kontogiannis V; Coughlan D; Richmond C; Eastaugh CH; Beyer FR; Pearson F; Craig D; Lovat P; Vale L; Ellis R
BMJ Open; 2023 Sep; 13(9):e073306. PubMed ID: 37770261
[TBL] [Abstract][Full Text] [Related]
26. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy.
Arnot SP; Han G; Fortino J; Han D; Fowler G; Vetto JT
Am J Surg; 2021 Jun; 221(6):1195-1199. PubMed ID: 33773750
[TBL] [Abstract][Full Text] [Related]
27. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging.
Schuitevoerder D; Heath M; Cook RW; Covington KR; Fortino J; Leachman S; Vetto JT
J Drugs Dermatol; 2018 Feb; 17(2):196-199. PubMed ID: 29462228
[TBL] [Abstract][Full Text] [Related]
28. Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study.
Podlipnik S; Carrera C; Boada A; Richarz NA; López-Estebaranz JL; Pinedo-Moraleda F; Elosua-González M; Martín-González MM; Carrillo-Gijón R; Redondo P; Moreno E; Malvehy J; Puig S
J Eur Acad Dermatol Venereol; 2019 May; 33(5):857-862. PubMed ID: 30702163
[TBL] [Abstract][Full Text] [Related]
29. The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma.
Jarell A; Skenderis B; Dillon LD; Dillon K; Martin B; Quick AP; Siegel JJ; Rackley BB; Cook RW
Future Oncol; 2021 Dec; 17(36):5023-5031. PubMed ID: 34587770
[TBL] [Abstract][Full Text] [Related]
30. Prognostic models for predicting relapse or recurrence of major depressive disorder in adults.
Moriarty AS; Meader N; Snell KI; Riley RD; Paton LW; Chew-Graham CA; Gilbody S; Churchill R; Phillips RS; Ali S; McMillan D
Cochrane Database Syst Rev; 2021 May; 5(5):CD013491. PubMed ID: 33956992
[TBL] [Abstract][Full Text] [Related]
31. Assessing Genetic Expression Profiles in Melanoma Prognosis.
Farberg AS; Glazer AM; Winkelmann RR; Rigel DS
Dermatol Clin; 2017 Oct; 35(4):545-550. PubMed ID: 28886811
[TBL] [Abstract][Full Text] [Related]
32. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma.
Turner RM; Bell KJ; Morton RL; Hayen A; Francken AB; Howard K; Armstrong B; Thompson JF; Irwig L
J Clin Oncol; 2011 Dec; 29(35):4641-6. PubMed ID: 22067399
[TBL] [Abstract][Full Text] [Related]
33. Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test.
Ahmed K; Siegel JJ; Morgan-Linnell SK; LiPira K
Cancer Med; 2023 Jan; 12(2):2008-2015. PubMed ID: 35915969
[TBL] [Abstract][Full Text] [Related]
34. Association between traditional clinical high-risk features and gene expression profile classification in uveal melanoma.
Nguyen BT; Kim RS; Bretana ME; Kegley E; Schefler AC
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):421-427. PubMed ID: 29185101
[TBL] [Abstract][Full Text] [Related]
35. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
[TBL] [Abstract][Full Text] [Related]
36. Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations.
Hyams DM; Covington KR; Johnson CE; Plasseraud KM; Cook RW
Future Oncol; 2021 Feb; 17(5):517-527. PubMed ID: 33021104
[No Abstract] [Full Text] [Related]
37. Development and validation of a nomogram incorporating gene expression profiling and clinical factors for accurate prediction of metastasis in patients with cutaneous melanoma following Mohs micrographic surgery.
Thorpe RB; Covington KR; Caruso HG; Quick AP; Zolochevska O; Bricca GM; Campoli M; DeBloom JR; Fazio MJ; Greenhaw BN; Kirkland EB; Machan ML; Brodland DG; Zitelli JA
J Am Acad Dermatol; 2022 Apr; 86(4):846-853. PubMed ID: 34808324
[TBL] [Abstract][Full Text] [Related]
38. Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
Wisco OJ; Marson JW; Litchman GH; Brownstone N; Covington KR; Martin BJ; Quick AP; Siegel JJ; Caruso HG; Cook RW; Winkelmann RR; Rigel DS
Melanoma Res; 2022 Apr; 32(2):98-102. PubMed ID: 35254332
[TBL] [Abstract][Full Text] [Related]
39. Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer Stage I or II.
Lee JE; Lu M; Mansfield PF; Platsoucas CD; Reveille JD; Ross MI
Cancer; 1996 Aug; 78(4):758-63. PubMed ID: 8756369
[TBL] [Abstract][Full Text] [Related]
40. Factors Affecting Dermatologists' Use of a 31-Gene Expression Profiling Test as an Adjunct for Predicting Metastatic Risk in Cutaneous Melanoma.
Svoboda RM; Glazer AM; Farberg AS; Rigel DS
J Drugs Dermatol; 2018 May; 17(5):544-547. PubMed ID: 29742186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
